Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib in RDEB Associated Squamous Cell Carcinoma
NCT03786237Phase 2Completed
- Start
- Apr 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rigosertib in squamous cell carcinoma (SCC). Started Apr 2021; status: completed.
02
Drugs
rigosertib
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT03786237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786237.